Anlotinib combo for HR+ breast cancer that has spread
Part of Cancer clinical trials.
This trial tests a combination treatment including anlotinib for women with hormone receptor-positive breast cancer that has spread to other parts of the body and has stopped responding to standard therapies. It is for those who have already tried a CDK4/6 inhibitor and endocrine therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 18 and 75 years old
- You have hormone receptor-positive, HER2-negative breast cancer that has spread
- You have already received at least one type of CDK4/6 inhibitor and hormone therapy
- Your cancer got worse while on an aromatase inhibitor or fulvestrant combined with a CDK4/6 inhibitor
- You have no remaining standard treatment options left and are in generally good health (ECOG score 0-1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two cancer drugs (eribulin and anlotinib) for women whose breast cancer has spread and stopped responding to previous treatments, particularly antibody-drug conjugates. The study aims to see if this combination can help slow or shrink the cancer.
This trial tests adding entinostat (a drug that may help hormone therapy work better) to anlotinib or fulvestrant for people with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy and a CDK4/6 inhibitor. It aims to find a new treatment option for those who cannot use chemotherapy yet.
This trial tests adding anlotinib (a targeted therapy) and benmelstobart (an immunotherapy) to standard chemotherapy before surgery for a specific type of breast cancer. It may help shrink tumors and improve outcomes for patients whose tumors have certain markers.
This trial tests a combination of two targeted drugs — anlotinib (which cuts off a tumor's blood supply) and trastuzumab deruxtecan (which attacks HER2-low cancer cells) — for advanced breast cancer that has stopped responding to previous treatments.
This trial tests a combination of two drugs (camrelizumab and anlotinib) for patients with a specific type of endometrial cancer that has returned or spread. The drug combo aims to boost your immune system to fight the cancer while also cutting off its blood supply. It is for patients whose tumor has a certain genetic feature and who have already tried chemotherapy.
This trial tests a combination of two drugs, anlotinib and TQB2450, for people with advanced endometrial cancer that has not responded to previous chemotherapy. The goal is to see if this combination can help control the cancer.
Hear when a new HR+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.